BioVie (NASDAQ:BIVI) Announces Quarterly Earnings Results

BioVie (NASDAQ:BIVI) released its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share for the quarter, Zacks reports.

BioVie Price Performance

BioVie stock traded down $0.06 during mid-day trading on Tuesday, hitting $1.80. 400,384 shares of the company were exchanged, compared to its average volume of 949,359. The business’s 50 day simple moving average is $2.20 and its two-hundred day simple moving average is $2.29. The company has a market capitalization of $31.99 million, a P/E ratio of -0.16 and a beta of 0.47. BioVie has a 12-month low of $1.04 and a 12-month high of $33.10.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.